By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Cannabis NewsCannabis News
  • Cannabis
  • CBD
  • Science
  • Culture & Arts
  • Cannabis Press Releases
  • More
    • About Maryjanes Post
    • Cannabis Advertising
    • Cannabis Partnerships
Reading: News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19
Share
Aa
Aa
Cannabis NewsCannabis News
Search
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • About Maryjanes Post
    • Ambassador
    • Cannabis Partnerships
Follow US
  • Ad Choices
  • RSS Terms of Service
© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.
Cannabis News > Cannabis Press Releases > News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19
Cannabis Press Releases

News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19

Business Wire
Last updated: 2022/02/15 at 2:00 PM
Business Wire Published February 15, 2022
Share
SHARE

 – Chief Executive Officer and Chief Scientific Officer Interviewed About Pipeline and Pharma Trends –

BERWYN, Pa.–(BUSINESS WIRE)–#pharma–Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, as well as PTSD, CNS disorders and anti-viral indications, has been featured in several news outlets discussing potential solutions for two pressing issues: the opioid epidemic and the COVID pandemic.

New Logo Cannabis Media & PR

An article published by BioBuzz titled “Pain Management Company Virpax Sees Promise in Potential COVID-19 Antiviral OTC” focuses on the drug candidate, AnQlar™, an intranasal molecular masking spray in development as an anti-viral over-the-counter (OTC) product for protection against respiratory infections, such as SARS-CoV-2, and influenza. The article also discusses Virpax’s non-addictive pain management drug candidates: Epoladerm™ for pain associated with osteoarthritis of the knee and Probudur™, a local anesthetic for post-surgical pain.

An article published by BioSpace titled “How Pharma and Academia are Tackling the Opioid Epidemic” includes insight from Anthony Mack, CEO of Virpax, about the opioid crisis and the company’s development of non-addictive pain management solutions. Along with AnQlar, Epoladerm, and Probudur, Mack discusses Envelta™, Virpax’s investigational endogenous enkephalin intranasal spray for acute and chronic pain, including pain associated with cancer.

Having more than 35 years of experience in the pharmaceutical and finance industry, Mack is often quoted in the media discussing trends, predications, and current news events. Scrip included his insight on the M&A sector in the article “Scrip Asks…What Does 2022 Hold For Biopharma? Part 2: Deal Making, M&A And Financial Markets” and PharmaVoice included his prediction on targeted drug delivery in the article “20 Years in the Making: Reflections and Predictions”.

Dr. Sheila Mathias, Chief Scientific Officer of Virpax, was interviewed on PharmaVoice’s Woman of the Week (WOW) podcast discussing her leadership skills and the Virpax portfolio of products in development.

The articles at the links above are provided for informational purposes only. Virpax is not responsible for the content of the linked articles.

About Virpax Pharmaceuticals

Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval of its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal Molecular-Envelope Technology (MET) enkephalin formulation being developed for the management cancer and non-cancer pain, as well as post-traumatic stress disorder (PTSD) under the name PES200. MET technology is also used in AnQlar™, a candidate to inhibit viral replication caused by influenza or SARS-CoV-2. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults. For more information, please visit www.virpaxpharma.com.

Forward-Looking Statement

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on the Company’s operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

Media:
Laura Radocaj

DGI

212-825-3210

You Might Also Like

 Flower One Obtains Meeting Order Under the Companies’ Creditors Arrangement Act (Canada)

United States Alternative Adult Beverages Market Report 2022: The Burgeoning Adult Beverage Segment Expanding the Adult Beverage Horizon – ResearchAndMarkets.com

Global Cannabidiol Market Report 2022: Growing Acceptance and Use of Products Due to Government Approvals Drives Sector – ResearchAndMarkets.com

Organigram Launches HOLY MOUNTAIN to Further Support Its Strong Position in the Dried Flower and Hash Categories

Leafly to Participate at Upcoming Investor Conferences

TAGGED: Business Wire
Business Wire February 15, 2022
Share this Article
Twitter Reddit Email Copy Link
Previous Article Boost Insurance Powers First and Only Crypto Wallet Insurance Product for Retail Investors
Next Article Akanda Corp. Names Dr. Sunny Nayee as U.K. Medical Director to Support Partnership with Cellen Life Sciences

Cannabis News and More

Work with an experienced cannabis media firm to provide your brand with the exposure it needs.

Cannabis Topics

  • Cannabis
  • Business
  • CBD
  • Cannabis Science
  • Culture & Arts

Company

  • About Maryjanes Post
  • Contact Cannabis Media
  • Contributor Guidelines

Terms of Use

  • TERMS
  • PRIVACY
  • CONTRIBUTOR AGREEMENT
  • DMCA

Resources

  • Write For UsNew
  • Media KitNew
  • Cannabis Advertising
  • Cannabis Partnerships
  • Cannabis Press ReleaseNew
Cannabis NewsCannabis News
Follow US

© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.

  • Ad Choices
  • RSS Terms of Service
Go to mobile version
Welcome Back!

Sign in to your account

Lost your password?